Sanofi Consumer Healthcare India Limited announced the designation of two key executives as Senior Management Personnel (SMP) effective February 25, 2026. Ms. Nupur Gurbaxani, Director, Brand & Innovation, and Mr. Viral Shah, Director, External Manufacturing, received this appointment following a recommendation from the Nomination & Remuneration Committee. Both individuals bring extensive industry experience to their expanded roles, focusing on brand transformation and strengthening manufacturing capabilities, respectively.
Appointment of Senior Management Personnel
The Board of Directors of Sanofi Consumer Healthcare India Limited, in its meeting held on February 25, 2026, officially designated two key personnel as Senior Management Personnel (SMP). This action was taken based on the recommendation of the Nomination & Remuneration Committee.
The newly designated SMPs, effective the same day, February 25, 2026, are:
- Ms. Nupur Gurbaxani, Director, Brand & Innovation. (Designation date: 22nd July 2024)
- Mr. Viral Shah, Director, External Manufacturing. (Designation date: 13th May 2024)
Executive Profile Highlights
Ms. Nupur Gurbaxani
Ms. Gurbaxani is identified as a senior commercial leader for Sanofi Consumer. Since joining in July 2024, she has been credited with driving brand penetration turnaround through sharp insights and innovative digital-first campaigns. She holds over 18 years of rich experience from major organizations including Godrej Consumer Products, Novartis, and Abbott Nutrition. Her mandate will involve playing a critical role in the company’s journey of brand transformation.
Mr. Viral Shah
Mr. Shah is designated as a senior manufacturing leader. Since joining in May 2024, he has focused on developing infrastructure and establishing partnerships for the company’s “Make In India” initiatives across products. Mr. Shah possesses over 20 years of extensive experience from reputed pharmaceutical companies such as Torrent, Ranbaxy Laboratories, Merck & Co., and Bayer. His focus will be on strengthening manufacturing capabilities and accelerating export growth from India.
Regulatory Compliance Note
The disclosure of these appointments is made pursuant to the requirements of Regulation 30 of the relevant securities regulations. The Board meeting where this designation was approved commenced at 2:00 p.m. and concluded at 5:20 p.m. on the date of the announcement.
Source: BSE
